Simon To - HUTCHMED DRC Executive Chairman of the Board
| HCM Stock | USD 18.16 0.83 4.37% |
Chairman
Mr. Simon To is Executive Chairman of the Board of Hutchison China MediTech Ltd. He is also Chairman of the Remuneration C o m m i t t e e a n d a member of the Technical Committee of the Company. He is managing director of Hutchison Whampoa Limited and was with Hutchison China for over thirty years, building its business from a small trading company to a billion dollar investment group. He has negotiated major transactions with multinationals such as Procter Gamble, Lockheed, Pirelli, Beiersdorf, United Airlines and British Airways. Mr Tos career in China spans more than thirty years and he is well known to many of the top Government leaders in China. Mr To is the original founder of Hutchison Whampoa Limiteds TCM business and was instrumental in the acquisitions made to date. He received a First Class Honours Bachelors Degree in Mechanical Engineering from Imperial College, London and an MBA from Stanford Universitys Graduate School of Business. since 2006.
| Age | 62 |
| Tenure | 18 years |
| Professional Marks | MBA |
| Address | Cheung Kong Center, Hong Kong, Hong Kong |
| Phone | 852 2121 8200 |
| Web | https://www.hutch-med.com |
HUTCHMED DRC Management Efficiency
As of the 27th of April 2024, Return On Tangible Assets is likely to grow to 0.08. Also, Return On Capital Employed is likely to grow to 0.02. At this time, HUTCHMED DRC's Return On Assets are very stable compared to the past year. HUTCHMED DRC's management efficiency ratios could be used to measure how well HUTCHMED DRC manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 12 records | CHAIRMAN Age | ||
| Ruben Minski | Procaps Group SA | 71 | |
| Michael Heffernan | Collegium Pharmaceutical | 53 | |
| Richard Pops | Alkermes Plc | 62 | |
| Jay Moorin | Eagle Pharmaceuticals | 62 | |
| Michael Campbell | Regencell Bioscience Holdings | 62 | |
| David Stack | Pacira Pharmaceuticals | 74 | |
| Bryan Roberts | Ironwood Pharmaceuticals | 47 | |
| Sharon Mates | Intracellular Th | 71 | |
| Jacques Vaillancourt | Regencell Bioscience Holdings | N/A | |
| Jack Bendheim | Phibro Animal Health | 77 | |
| Ronald Lombardi | Prestige Brand Holdings | 60 | |
| Robert Brown | ANI Pharmaceuticals | 67 | |
Management Performance
| Return On Equity | 0.15 | ||||
| Return On Asset | 0.01 |
HUTCHMED DRC Leadership Team
Elected by the shareholders, the HUTCHMED DRC's board of directors comprises two types of representatives: HUTCHMED DRC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of HUTCHMED. The board's role is to monitor HUTCHMED DRC's management team and ensure that shareholders' interests are well served. HUTCHMED DRC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, HUTCHMED DRC's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Eishi Fukumoto, Executive Officer, Chief Director of Research | ||
| Tetsuo Katsurayama, Executive Officer, Chief Director of Finance | ||
| Genroku Sugiyama, Executive Officer, Director of India Business | ||
| Shigeru Endo, Non-Executive Director | ||
| Selina Zhang, Senior Resources | ||
| Graeme Jack, Independent Non-Executive Director | ||
| Masato Tamaki, Executive Officer, CIO, Chief Director of IT Promotion | ||
| Koji Sumioka, Executive Officer, Director of Japan Business and Presidentident of Subsidiary | ||
| Simon To, Executive Chairman of the Board | ||
| Hong Chen, Senior China | ||
| Kenji Ohta, Executive Officer, Deputy Chief Director of Sales, Chief Director of Life Cycle Support Business | ||
| Paul Carter, Senior Independent Non-Executive Director | ||
| Edith Shih, Company Secretary, Non-Executive Director | ||
| Yasushi Ochiai, Managing Executive Officer, Chief Director of Sales | ||
| Tsutomu Mizutani, Senior Managing Executive Officer, Director of China Business, Director | ||
| Takashi Kawamura, Independent Chairman of the Board of Directors | ||
| BSE CS, Company Director | ||
| Toshihiro Ohno, Executive Officer, Chief Director of Development, Chief Director of PDI | ||
| Osamu Okada, Director | ||
| ACGI BSc, Ex Chairman | ||
| Yukio Arima, Senior Managing Executive Officer, Chief Director of Strategy Planning, Chief Director of Business Administration, Director | ||
| Chig Cheng, CFO, Executive Director | ||
| Mitsuhiro Tabei, Managing Executive Officer, Chief Director of Marketing, Director | ||
| CA BEc, CFO Director | ||
| CS CGP, Company Director | ||
| Christian Salbaing, Non-Executive Director | ||
| Christian Hogg, CEO, Executive Director | ||
| Weiguo Su, Executive Director | ||
| Karen Atkin, Executive COO | ||
| Hisashi Hasegawa, Executive Officer, Chief Human Resource Officer, Chief Director of Human Resources | ||
| Kotaro Hirano, Executive Officer, Chief Director of Business Administration | ||
| Hiroshi Tokushige, Executive Vice President Representative Executive Officer, Chief Director of Export Management, Leader of C Project, Director | ||
| Christopher Nash, Senior Independent Non-Executive Director | ||
| Akihiko Hiraoka, Managing Executive Officer, Deputy Chief Director of China Business, General Manager of Subsidiary | ||
| Takayoshi Ikeda, Executive Officer, Deputy Chief Director of China Business, General Manager of Subsidiary | ||
| Shigeru Azuhata, Independent Director | ||
| Kin MBA, Senior Communications | ||
| Michifumi Tabuchi, Executive Officer, Director of China Business, General Manager of Subsidiary | ||
| Takuro Sato, Director of Legal Affairs | ||
| Charles Nixon, Group Counsel | ||
| Qingmei Wang, Senior Alliances | ||
| Karen Ferrante, Non-Executive Independent Director | ||
| Yuichi Tsujimoto, Executive President Representative Executive Officer, Director | ||
| Shu Mok, Non-Executive Independent Director | ||
| Michael Howell, Independent Non-Executive Director | ||
| Christopher Huang, Independent Non-Executive Director | ||
| David Ng, Head Strategies | ||
| Dan Eldar, Non-Executive Director | ||
| Tadashi Motoi, Executive Officer, Deputy Chief Director of Asian & Oceanian Business and Presidentident of Subsidiary | ||
| Hideto Mitamura, Independent Director | ||
| Weiguo BSc, Chief CEO | ||
| Morio Sumiya, Executive Officer, Director of Europe & Middle East Business and Presidentident of Subsidiary |
HUTCHMED Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is HUTCHMED DRC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.15 | ||||
| Return On Asset | 0.01 | ||||
| Profit Margin | 0.12 % | ||||
| Operating Margin | (0.31) % | ||||
| Current Valuation | 30.64 B | ||||
| Shares Outstanding | 170.73 M | ||||
| Shares Owned By Insiders | 0.12 % | ||||
| Shares Owned By Institutions | 9.40 % | ||||
| Number Of Shares Shorted | 515.84 K | ||||
| Price To Earning | 335.94 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards HUTCHMED DRC in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, HUTCHMED DRC's short interest history, or implied volatility extrapolated from HUTCHMED DRC options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in HUTCHMED DRC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in HUTCHMED Stock, please use our How to Invest in HUTCHMED DRC guide.Note that the HUTCHMED DRC information on this page should be used as a complementary analysis to other HUTCHMED DRC's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Complementary Tools for HUTCHMED Stock analysis
When running HUTCHMED DRC's price analysis, check to measure HUTCHMED DRC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HUTCHMED DRC is operating at the current time. Most of HUTCHMED DRC's value examination focuses on studying past and present price action to predict the probability of HUTCHMED DRC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HUTCHMED DRC's price. Additionally, you may evaluate how the addition of HUTCHMED DRC to your portfolios can decrease your overall portfolio volatility.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |
Is HUTCHMED DRC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of HUTCHMED DRC. If investors know HUTCHMED will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about HUTCHMED DRC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.6 | Revenue Per Share 4.93 | Quarterly Revenue Growth 0.36 | Return On Assets 0.01 | Return On Equity 0.1465 |
The market value of HUTCHMED DRC is measured differently than its book value, which is the value of HUTCHMED that is recorded on the company's balance sheet. Investors also form their own opinion of HUTCHMED DRC's value that differs from its market value or its book value, called intrinsic value, which is HUTCHMED DRC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because HUTCHMED DRC's market value can be influenced by many factors that don't directly affect HUTCHMED DRC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between HUTCHMED DRC's value and its price as these two are different measures arrived at by different means. Investors typically determine if HUTCHMED DRC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, HUTCHMED DRC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.